BostonGene Stock
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
Sign up today and learn more about BostonGene Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BostonGene Stock
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
Funding History
April 2019 | $50.0M |
---|---|
April 2022 | $150M |
Management
President & CEO
Andrew Feinberg
Press
patents - Apr, 14 2024
Systems and methods for predicting therapy efficacy from normalized biomarker …patents - Apr, 14 2024
Urothelial tumor microenvironment (tme) typespatents - Apr, 14 2024
Machine learning techniques for tertiary lymphoid structure (tls) detectionpatents - Apr, 14 2024
Cytokine gene expression signaturespatents - Apr, 14 2024
Techniques for detecting homologous recombination deficiency (hrd)